HOME >> MEDICINE >> NEWS
Results of exercise test may predict death in patients with coronary artery disease

Exercise capacity, as measured in terms of VO2max, is a powerful predictor of death in patients with coronary artery disease, not just patients with heart failure. That is the finding of Mayo Clinic research presented today at the American Heart Association's Scientific Sessions 2005 in Dallas.

VO2max is the maximum amount of oxygen a person can take in during exercise. In a VO2max study, a patient walks on a treadmill for about 5 to 15 minutes and breathes through a valve; the oxygen and carbon dioxide in the expired air are measured. Results are given in milliliters of oxygen per kilogram of body weight per minute (ml/kg/min).

"The best predictor of survival in cardiac patients is their capacity for exercise," says Thomas Allison, Ph.D., the lead author of the study, who is from Mayo Clinic in Rochester, Minn. "When we considered all of the measurable clinical variables -- such as whether they had bypass surgery or whether they have diabetes or high blood pressure -- the patient's capacity for exercise as measured by VO2max stood clear as the best predictor for 10-year survival."

In this study, the significance of low VO2max levels was examined in patients with coronary artery disease -- the top cause of death in the United States and often a precursor to a heart attack and heart failure.

A group of 282 patients, 17 percent of them women, underwent cardiopulmonary treadmill testing at the end of cardiac rehabilitation and were followed for an average of 9.8 years. The average age was 61 at the time of the test.

In the first two years there were few deaths, but after that mortality was significantly higher in patients with low VO2max. Fifty-five patients had a low VO2max (less than 18 ml/kg/min); at 10 years, almost half (42 percent) had died. Of the 227 patients who had a VO2max above or equal to 18 ml/kg/min, only 11.6 percent had died at the 10-year mark. Even after adjusting for age, sex and ventricular function, VO2ma
'"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005, 507-284-251
Mayo Clinic
14-Nov-2005


Page: 1 2

Related medicine news :

1. Results of largest ever genome scan for autism out
2. Timely treatment of heart attacks: Results from the AMI-QUEBEC Study
3. Results of hospital performance measures do not always reflect patient outcomes
4. Results good for HER-2 positive breast cancer patients using trastuzumab
5. Results of clipping and coiling of aneurysms are similar over time
6. Results with newer bladeless LASIK equivalent to standard microkeratome LASIK
7. Traditional Chinese exercises may increase efficacy of flu vaccine
8. Even low levels of weekly exercise drive down blood pressure
9. Some women benefit more from exercise when emphasis is on health, not appearance
10. Strengthening exercises may slow progression of ALS
11. Research shows aerobic exercise helps maintain muscle in elderly

Post Your Comments:
(Date:2/28/2015)... Ohio (PRWEB) February 28, 2015 ... Motivational? Supportive? Strategic? , There are all kinds ... strengths. To raise awareness of the advantages and ... firm PeopleKeys is launching a new product this ... clients better understand the connection between personality type, ...
(Date:2/28/2015)... The noted Friedman Dental Group of ... officially relaunched their website. The new version of the ... a new section about their team members. Potential and ... biographies of each Friedman Dental Group team member including ... designed to provide our patients with the opportunity to ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Developers of ... of a new overlay plugin for Final Cut Pro X ... , “FCPX Overlay Chromatic gives users total control over 6k ... Austin, CEO of Pixel Film Studios. “FCPX Overlay Chromatic was ... easy to use interface.” , FCPX Overlay Chromatic Grunge 6K ...
(Date:2/28/2015)... Powermod ” was featured on NewsWatch as part of its ... and coolest technology products and services available to consumers. Scott ... conducted the review and shared with viewers how they provide ... a low battery and no way to charge a phone ... daily basis. Even when a person does have a charger, ...
(Date:2/28/2015)... Memphis, TN: MedixSafe has retracted a ... new security reader named Guardian 2. The correct ... new biometric scanner that significantly increases the complexity ... new biometric scanner provides fast and easy access ... narcotics lockers with Vanguard technology tracks ...
Breaking Medicine News(10 mins):Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
(Date:2/27/2015)... SOUTH PLAINFIELD, N.J., Feb. 27, 2015  PTC Therapeutics, ... corporate update and reported financial results for the fourth ... "2014 was a transformative year for PTC. ... on delivering and developing RNA-targeted therapies in the rare ... Officer, PTC Therapeutics, Inc. "We are proud to bring ...
(Date:2/27/2015)... -- Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today announced that it will ... March 10, 2015. Rob Kill , President and ... will present at 4:00 p.m. Pacific Time and meet ... the Ritz Carlton in Laguna Niguel, CA. ...
Breaking Medicine Technology:Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Uroplasty to Participate in the 27th Annual ROTH Conference 2
Cached News: